Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Soleno Therapeutics, Inc. (NASDAQ: SLNO) provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Soleno describes itself as a biopharmaceutical company focused on novel therapeutics for rare diseases, and its filings document financial results, material agreements, governance changes, and other significant events related to this business.
Investors can review current reports on Form 8-K in which Soleno announces quarterly and preliminary financial results, operating metrics for VYKAT XR (diazoxide choline) extended-release tablets, and updates on the U.S. launch of this once-daily oral treatment for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome. These filings incorporate press releases that discuss product revenue, profitability, cash balances, and other financial information.
Filings also describe capital structure and financing arrangements, including an accelerated share repurchase (ASR) Agreement with Jefferies LLC for up to $100 million of common stock and a first amendment to Soleno’s loan and security agreement with Oxford Finance LLC and other lenders. The 8-Ks outline key terms of these arrangements, such as prepayment of the purchase price, initial share delivery, and changes to loan availability.
Additional 8-Ks cover corporate governance and Board composition, such as the appointment of an independent director with extensive biopharmaceutical finance experience and the associated equity grants under the company’s equity incentive plan. Other filings provide Regulation FD disclosures on topics like investor presentations and safety-related communications, including Soleno’s description of a serious adverse event reported in the FDA’s FAERS database and its assessment of that event.
On this page, AI-powered tools can help summarize lengthy exhibits and press releases attached to Soleno’s filings, highlight key terms in material agreements, and clarify the implications of reported financial metrics, capital transactions, and governance changes for users reviewing SLNO’s regulatory history.
Soleno Therapeutics senior vice president of clinical development reported a routine share withholding transaction related to equity compensation. On December 15, 2025, the officer had 812 shares of common stock withheld by the company at a price of $49.95 per share to cover tax obligations arising from the vesting and settlement of restricted stock units (RSUs). After this tax withholding, the officer beneficially owned 36,005 shares of Soleno Therapeutics common stock. Some of these holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to vesting schedules and conditions.
Soleno Therapeutics officer and Senior Vice President of Regulatory Affairs reported an automatic share withholding related to vested restricted stock units (RSUs). On December 15, 2025, 904 shares of common stock were withheld by the company to cover the reporting person’s tax obligations upon RSU settlement at a price of $49.95 per share. After this tax withholding transaction, the insider beneficially owned 12,302 shares of Soleno Therapeutics common stock. Certain of the remaining holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to their vesting schedules and conditions.
Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported equity transactions in company stock. On December 15, 2025, 7,620 shares of common stock were withheld by the company at a price of $49.95 to cover tax obligations related to vested restricted stock units. On the same date, he transferred 100,000 shares of common stock as a gift, for no consideration, to two family trusts for the benefit of his descendants.
After these transactions, Bhatnagar beneficially owned 469,456 shares of Soleno Therapeutics common stock, some of which are in the form of restricted stock units, each representing a contingent right to receive one share subject to vesting conditions. He reports beneficial ownership of the gifted shares only to the extent of any pecuniary interest and disclaims beneficial ownership of the shares held by the trusts.
Soleno Therapeutics (SLNO) reported an equity award and option activity for its Chief Business Officer. On 11/17/2025, the officer acquired 14,286 restricted stock units (RSUs) of common stock at a price of $0, all held directly after the transaction. Each RSU represents the right to receive one share of common stock.
One-half of these RSUs will vest on November 17, 2026, with one third of the remaining units vesting on each one-year anniversary after that, as long as the officer continues as a service provider. The filing also shows an employee stock option covering 64,286 shares of common stock at an exercise price of $47.25 per share, expiring on 11/17/2035. One-fourth of the option shares will vest on November 17, 2026, and one forty-eighth of the shares will vest monthly thereafter, subject to continued service.
Soleno Therapeutics Inc. (SLNO) disclosed a new insider reporting status for its Chief Business Officer through a Form 3 filing. This form identifies the individual as an officer of the company and confirms that the filing is made by a single reporting person. The filing states in the remarks that no securities are beneficially owned, meaning the officer reports holding no Soleno shares or derivative securities as of the event date.
Soleno Therapeutics (SLNO) reported an insider ownership update via a Form 3. The filing identifies the reporting person as an Officer (Chief Development Officer) and states that no securities are beneficially owned as of the event date 11/10/2025. The document serves as an initial statement of ownership under Section 16 and was signed by an attorney-in-fact.
Soleno Therapeutics entered an accelerated share repurchase with Jefferies to repurchase $100.0 million of common stock. The Company prepaid $100.0 million and received an initial delivery of 1,511,553 shares, with any remaining shares expected by the end of its first fiscal quarter of 2026. The final share count will be based on the stock’s volume‑weighted average price during the program, less an agreed discount, with settlement adjustments that could require either party to deliver additional shares or, in Soleno’s case, make a cash payment.
In connection with the ASR, Soleno amended its Oxford Finance loan agreement to permit the repurchase and to modify previously committed capacity. Lenders are no longer obligated to fund the $25.0 million Term C Loans or $25.0 million Term D Loans. After the amendment, the remaining $100.0 million of loans is uncommitted and may be made available only upon mutual agreement.
Soleno Therapeutics (SLNO) reported its first profitable quarter as a commercial company. For Q3 2025, product revenue was $66.0 million, driving operating income of $22.1 million and net income of $26.0 million. Year-to-date, product revenue reached $98.7 million. The company began recognizing sales after the FDA approved VYKAT XR in March 2025 to treat hyperphagia in Prader-Willi syndrome and first prescriptions shipped in April.
Liquidity strengthened significantly: cash and cash equivalents were $246.7 million and marketable securities were $309.4 million at September 30, 2025. In July, Soleno completed an underwritten offering of 2,705,882 shares at $85.00 per share for gross proceeds of $230.0 million (approximately $14.3 million in offering costs). Long-term debt outstanding was $50.0 million under the Oxford facility, with additional tranches available subject to terms. Shares outstanding were 53,710,025 as of October 31, 2025.
Soleno Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended September 30, 2025. The company reported these quarterly results through a press release dated November 4, 2025, which is attached as Exhibit 99.1 to this report and incorporated by reference.
The information is provided under the “Results of Operations and Financial Condition” section of the rules governing current reports and is designated as furnished rather than filed. This means it is not subject to certain liability provisions and is not automatically included in other securities law filings unless specifically referenced.
Soleno Therapeutics (SLNO) disclosed a director equity award. On 10/13/2025, the reporting person was granted 10,046 restricted stock units (RSUs) at $0. Each RSU represents the right to receive one share of common stock.
Vesting: one-third on October 13, 2026 and on each one-year anniversary thereafter, subject to continued service. Beneficial ownership following the grant was 10,046 shares, held directly.